Skip to main content
SpringerLink
Log in

DA-EPOCH-R: An alternative treatment for high-risk diffuse large B cell lymphoma?

Treatment intensity and outcome in newly diagnosed myeloma patients

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with an annual incidence of 7–8 cases per 100,000 per year. With standard induction therapy comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R/CHOP), 40% of all patients get cured. Patients relapsing or being refractory to R/CHOP have a poor prognosis with a 10 % cure rate. On the other hand, the prognosis for patients with an event-free survival of 24 months is excellent. Despite the possibility of identifying patients at high risk for R/CHOP failure at the time of diagnosis, to date, an adequate risk-adapted induction has not been established. Dose-adjusted application of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) is a pharmacodynamic approach to improve R/CHOP by the addition of etoposide, prolonged exposure to chemotherapy agents (continuous infusion of etoposide, vincristine, and doxorubicin over 96 h) and dose adjustment based on the absolute neutrophil count nadir. DA-EPOCH-R has shown promising results in retrospective analyses of various high-risk DLBCL cases. The following article reviews various approaches to define and to treat patients with high-risk DLBCL with a focus on treatment with DA-EPOCH-R.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patents in the LNH-98.5 trial, the first randomized study comparing rituximab CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d Etudes des Lymphomes de l Adulte. Blood. 2010;116:2040.

    Article  CAS  Google Scholar 

  2. Maurer MJ, Ghesquières H, Jais J‑P. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B‑Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2014;32(10):1066–73.

    Article  Google Scholar 

  3. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184.

    Article  Google Scholar 

  4. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B‑cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.

    Article  CAS  Google Scholar 

  5. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B‑cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–7.

    Article  Google Scholar 

  6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B‑cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

    Article  CAS  Google Scholar 

  7. de Jong D, Rosenwald A, Chhanabhai M, et al. Lunenburg Lymphoma Biomarker Consortium. Immunohistochemical prognostic markers in diffuse large B‑cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805–12.

    Article  Google Scholar 

  8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B‑cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

    Article  CAS  Google Scholar 

  9. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.

    Article  Google Scholar 

  10. Lenz G, Wright G, Dave SS, et al. Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23.

    Article  CAS  Google Scholar 

  11. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417–29.

    Article  CAS  Google Scholar 

  12. Pasqualucci L. The genetic basis of diffuse large B‑cell lymphoma. Curr Opin Hematol. 2013;20(4):336–44.

    Article  CAS  Google Scholar 

  13. Roschewski M, Staudt LM. Wilson WH Diffuse large B‑cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23.

    Article  CAS  Google Scholar 

  14. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B‑cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–5.

    Article  CAS  Google Scholar 

  15. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B‑cell lymphoma patients treated with R‑CHOP chemotherapy. Blood. 2009;114(17):3533–7.

    Article  CAS  Google Scholar 

  16. Friedberg JW. Double-hit diffuse large B‑cell lymphoma. J Clin Oncol. 2012;30(28):3439–43.

    Article  CAS  Google Scholar 

  17. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of Myc and BCL2 in diffuse large B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristin and prednisone. J Clin Oncol. 2012;30:3460.

    Article  Google Scholar 

  18. Green TM, Young KH, Visco C, et al. Immunhistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. J Clin Oncol. 2012;30:3460.

    Article  CAS  Google Scholar 

  19. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression ontributes to the inferior survival of activated B cell subtype of diffuse large B cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021.

    Article  CAS  Google Scholar 

  20. Hertzberg MS, Gandhi MK, Butcher B, et al. Early treatment intensification with R‑ICE chemotherapy followed by autologous stem cell transplantation (ASCT) using Zevalin-BEAM for patients with poor risk dffuse large B‑cell lymphoma (DLBCL) as identified by interim PET/CT scan performed after four cycles of R‑CHOP-14: a multicenter phase II study of the australasian leukaemia lymphoma study group (ALLG). Blood. 2015;126:815.

    Google Scholar 

  21. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681.

    Article  CAS  Google Scholar 

  22. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B‑cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–9.

    Article  CAS  Google Scholar 

  23. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B‑cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–67.

    Article  Google Scholar 

  24. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8‑year follow-up of study of EPOCH. J Clin Oncol. 2000;18:3633–42.

    Article  CAS  Google Scholar 

  25. Lai G‑M, Chen Y‑N, Mickley LA, et al. P‑glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696–703.

    Article  CAS  Google Scholar 

  26. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B‑cell lymphoma. N Engl J Med. 2013;368(15):1408–16.

    Article  CAS  Google Scholar 

  27. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25.

    Article  CAS  Google Scholar 

  28. Cusack BJ, Young SP, Driskell J, et al. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol. 1993;32(1):53–8.

    Article  CAS  Google Scholar 

  29. Gharwan H, Lai C, Grant C, et al. Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B‑cell lymphomas. Leuk Lymphoma. 2016;57(7):1616–24.

    Article  CAS  Google Scholar 

  30. Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–9.

    Article  CAS  Google Scholar 

  31. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10036):2402–11.

    Article  CAS  Google Scholar 

  32. Dunleavy K, Fanale M, LaCasce A, et al. Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B‑Cell Lymphoma. Blood. 2014;124(21):395.

    Google Scholar 

  33. Dunleavy K, Pittaluga S, Wayne A, et al. Myc+ aggressive B‑cell lymphomas: novel therapy of untreated Burkitt Lymphoma (BL) and MYC+ diffuse large B‑cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol. 2011;22(Suppl 4):Abstract 71.2011.

    Google Scholar 

  34. Howlett C, Snedecor SJ, Landsburg DJ, et al. Front line dose escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double hit lymphoma: a systematic review and meta-analysis. Br J Haematol. 2015;170:504.

    Article  Google Scholar 

  35. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354.

    Article  CAS  Google Scholar 

  36. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891.

    Article  CAS  Google Scholar 

  37. Purroy N, Bergua J, Gallur, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B‑cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 2015;169:188–98.

    Article  CAS  Google Scholar 

  38. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B‑cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–93.

    Article  CAS  Google Scholar 

  39. Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B‑cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97:758–65.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Department of Medicine, Center for Haematology and Oncology, Hanusch-Hospital, Heinrich-Collin-Straße 30, 1140, Vienna, Austria

    Michael Panny & Thomas Nösslinger

Authors
  1. Michael Panny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Nösslinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Panny.

Ethics declarations

Conflict of interest

M. Panny and T. Nösslinger declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panny, M., Nösslinger, T. DA-EPOCH-R: An alternative treatment for high-risk diffuse large B cell lymphoma?. memo 9, 178–182 (2016). https://doi.org/10.1007/s12254-016-0290-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0290-4

Keywords

Search

Navigation